In This Section      
 

Search Results

Title:
Phase I Safety Study of Stereotactic Radiosurgery with Concurrent and Adjuvant PD-1 Antibody Nivolumab in Subjects with Recurrent or Metastatic Chordoma
Protocol Number:
J16138
Phase:
Phase I
Physician:
Michael Lim
Sites:
Johns Hopkins Kimmel Cancer Center in Baltimore
Purpose:
This research is being done to look at the safety of using stereotactic radiosurgery (SRS) and Nivolumab together to treat recurrent or advanced chordomas.
Eligibility:
People at least 15 years old with recurrent or advanced chordoma may be able to join. Patients must have adequate lab values and be able and willing to follow study requirements
Treatment:
You will receive nivolumab every 2 weeks. Nivolumab is administered by IV infusion, meaning the drug is given through a vein. The nivolumab infusion usually takes about 1 hour (60 minutes). An intravenous infusion pump will be used to ensure the correct amount of study drug is given over the proper amount of time. You will receive this treatment for up to 2 years. You will receive SRS to treat your brain or spine metastasis per standard of care about 7 days following the first dose of nivolumab.
Population:
Both
Last Update
03/05/2019 05:03 AM